Sub-group analysis indicates that anti-TRPM7 immunoreactivity in the primary pancreatic tumor that metastasized (n = 11) tends to be higher than that in non-metastatic pancreatic tumors (n = 266) (P = 0.06). Here, TRPM7 is linked to pancreatic neoplasm.